Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.

Some gonadal hormone drugs can block filovirus entry into cells.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.

Certain genetic mutations can lower bad cholesterol and reduce heart disease risk, leading to effective cholesterol-lowering drugs.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.

Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.

Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.

Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.

KATP channel openers may cause peripheral edema by reducing lymphatic contractions and flow.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Letrozole reduces seizures but not brain damage in mice.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Letrozole may help prevent seizures by reducing certain hormone levels.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Upadacitinib may effectively treat resistant lichen planopilaris.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.